In the Media Tag: Scott Howard

Cellworks CBM Clinical Study Identifies Novel Biomarkers for ATRA Benefit and Failure in AML Patients

Published by BizWire Express
In the Media Icon

Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from a Cellworks Clinical Trial, in which the Cellworks Computational Omics Biology Model (CBM) accurately predicted that All-Trans Retinoic Acid (ATRA) combined with cytarabine, etoposide, idarubicin (ATRA-CEI) benefits a subset of non-APL (Acute Promyelocytic… Read More

Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy

Published by BizWire Express
In the Media Icon

Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-021-01 clinical trial, which found that the Cellworks Omics Biology Model (CBM) predicted response to Arsenic Trioxide (ATO) and All-trans-retinoic Acid (ATRA) in Acute Promyelocytic Leukemia (APL) patients harboring PML-RARA fusions with… Read More